Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943226 | PMC |
| http://dx.doi.org/10.21037/tlcr.2018.03.23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PFKFB3-dependent redox homeostasis and DNA repair support cell survival under EGFR-TKIs in non-small cell lung carcinoma.
Cancer Metab
December 2024
Department of Medicine, School of Medicine, University of Louisville, Louisville, KY, 40202, USA.
Background: The efficacy of tyrosine kinase inhibitors (TKIs) targeting the EGFR is limited due to the persistence of drug-tolerant cell populations, leading to therapy resistance. Non-genetic mechanisms, such as metabolic rewiring, play a significant role in driving lung cancer cells into the drug-tolerant state, allowing them to persist under continuous drug treatment.
Methods: Our study employed a comprehensive approach to examine the impact of the glycolytic regulator 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) on the adaptivity of lung cancer cells to EGFR TKI therapies.
Risk of COVID-19 infection in patients with NSCLC receiving EGFR-TKI targeted therapy during the first wave in China.
J Int Med Res
October 2024
Lung Cancer Center, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Objective: We examined the factors influencing hospitalization and prognosis among patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeted therapy during the first wave of the coronavirus disease 2019 (COVID-19) pandemic.
Methods: In total, 267 patients diagnosed with NSCLC who were receiving treatment with third-generation EGFR-TKIs were included in our retrospective study. Data on patients' demographics, clinical characteristics, and survival were collected and analyzed.
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation.
Exp Hematol Oncol
October 2024
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Article Synopsis
- Aberrant activation of MET contributes to resistance against EGFR TKIs in EGFR-mutant non-small cell lung cancer (NSCLC), but the mechanisms are not fully understood and effective treatments are still being explored.
- The study created gefitinib-resistant NSCLC cell lines and investigated the interplay between MET and VEGF/VEGFR2 signaling using various molecular techniques, discovering a positive feedback loop that enhances signaling pathways.
- Combining MET inhibitors like crizotinib with anti-VEGF treatments, such as bevacizumab, significantly increased sensitivity to gefitinib and effectively reduced tumor growth in xenograft models and patients with EGFR/MET alterations.
Deciphering the Dynamics of EGFR-TKI Resistance in Lung Cancer: Insights from Bibliometric Analysis.
Drug Des Devel Ther
October 2024
Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
Article Synopsis
- EGFR-TKI resistance is a major challenge in treating non-small cell lung cancer (NSCLC), motivating detailed research into its mechanisms and potential strategies.
- A bibliometric analysis from 1996 to 2024 evaluated 8,051 publications using various software tools, revealing a significant increase in research productivity and collaborations, particularly among researchers from China, the US, and Japan.
- The findings highlight essential topics like first-generation EGFR-TKIs, the T790M mutation, and the role of emerging agents, emphasizing the importance of understanding resistance mechanisms for developing effective post-resistance treatments.
Immunotherapy plus Chemotherapy for Patients with EGFR-Mutated Non-Squamous Cell Lung Cancer for Disease Progression after EGFR Tyrosine-Kinase Inhibitor: A Meta-Analysis of Randomized Controlled Trials.
Oncology
September 2024
Oncology Department, King's College London, Jeddah, Saudi Arabia.
Introduction: Patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations face poor outcomes after progression on tyrosine kinase inhibitors (TKIs). The efficacy of immune checkpoint inhibitors (ICIs) combined with chemotherapy in these patients remains uncertain.
Methods: We searched for studies published between randomized controlled trials of ICIs in combination therapies in advanced NSCLC patients post-EGFR TKI progression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!